Effects of Prophylactic Use of Sirolimus on Bronchiolitis Obliterans Syndrome Development in Lung Transplant Recipients Vikas Y. Sacher, MD, Debra Fertel, MD, Karan Srivastava, BS, Anthony Panos, MD, Dao Nguyen, MD, Tammy Baxter, MD, Shirin Shafazand, MD, Si M. Pham, MD The Annals of Thoracic Surgery Volume 97, Issue 1, Pages 268-274 (January 2014) DOI: 10.1016/j.athoracsur.2013.07.072 Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Study enrollment and inclusion in the retrospective study. (AZA = azathioprine; BOS = bronchiolitis obliterans syndrome; MMF = mycophenolate mofetil; SIR = sirolimus.) The Annals of Thoracic Surgery 2014 97, 268-274DOI: (10.1016/j.athoracsur.2013.07.072) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Kaplan-Meier estimated freedom from bronchiolitis obliterans syndrome (BOS) till last follow-up. Patients who died, or lost to follow-up were censored. The Annals of Thoracic Surgery 2014 97, 268-274DOI: (10.1016/j.athoracsur.2013.07.072) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions
Fig 3 Kaplan-Meier estimated probability of overall survival till last follow-up. Patients lost to follow-up were censored. (MMF = mycophenolate mofetil.) The Annals of Thoracic Surgery 2014 97, 268-274DOI: (10.1016/j.athoracsur.2013.07.072) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions